{Reference Type}: Journal Article
{Title}: Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology.
{Author}: Porter C;Azam TU;Mohananey D;Kumar R;Chu J;Lenihan D;Dent S;Ganatra S;Beasley GS;Okwuosa T;
{Journal}: JACC CardioOncol
{Volume}: 4
{Issue}: 3
{Year}: Sep 2022
{Factor}: 8.422
{DOI}: 10.1016/j.jaccao.2022.07.005
{Abstract}: The field of cardio-oncology was born from the necessity for recognition and management of cardiovascular diseases among patients with cancer. This need for this specialty continues to grow as patients with cancer live longer as a result of lifesaving targeted and immunologic cancer therapies beyond the usual chemotherapy and/or radiation therapy. Often, potentially cardiotoxic anticancer treatment is necessary in patients with baseline cardiovascular disease. Moreover, patients may need to continue therapy in the setting of incident cancer therapy-associated cardiotoxicity. Herein, we present and discuss the concept of permissive cardiotoxicity as a novel term that represents an essential concept in the field of cardio-oncology and among practicing cardio-oncology specialists. It emphasizes a proactive rather than reactive approach to continuation of lifesaving cancer therapies in order to achieve the best oncologic outcome while mitigating associated and potentially off-target cardiotoxicities.